Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Apr 20, 2017
First patient dosed; combination trials with anti-PD-1 plus anti-CTLA-4 antibodies planned by year-end LEXINGTON, Mass., April 20, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced
Apr 05, 2017
Two posters presented at AACR show evidence of ASV™ synergizing with checkpoint blockade LEXINGTON, Mass., April 5, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immune checkpoint antibodies and cancer vaccines, today announced that
Mar 24, 2017
LEXINGTON, Mass., March 24, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced participation at the following conferences: The 7 th  Annual William Blair and Maidstone Life Sciences
Mar 09, 2017
- Will Host Update Conference Call at 11am ET Today - LEXINGTON, Mass. , March 9, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for
Feb 14, 2017
Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to royalty-bearing arrangements. Agenus to receive $80 million from Incyte: $60 million equity investment at $6 per share and $20 million in accelerated
Jan 30, 2017
- Appointment signals clinical focus - LEXINGTON, Mass., Jan. 30, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Jean-Marie Cuillerot, M.D.
Nov 14, 2016
LEXINGTON, Mass., Nov. 14, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today announced that the Company will present at the Jefferies 2016 London
Oct 27, 2016
Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass. , Oct. 27, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today provided an update
Jul 28, 2016
Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and
Jun 15, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present
Jun 08, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00